Back to Search
Start Over
Prevention of joint destruction in patients with high disease activity or high C-reactive protein levels: Post hoc analysis of the GO-FORTH study
- Source :
- Modern Rheumatology. 26:323-330
- Publication Year :
- 2015
- Publisher :
- Oxford University Press (OUP), 2015.
-
Abstract
- To assess the influence of golimumab dosage and disease activity on joint destruction in patients with active rheumatoid arthritis (RA) in the GO-FORTH study.Efficacy was compared among groups given basal methotrexate plus placebo, golimumab (50 mg), or golimumab (100 mg) with stratification by high (HDA) or moderate (MDA) baseline disease activity and by high or low baseline C-reactive protein (CRP).Among HDA or high CRP patients, the mean change of the total Sharp score was 3.48 and 3.41 in the placebo group, 1.94 and 2.71 in the 50 mg group, and 0.39 and 1.15 in the 100 mg group, respectively. The percentage of progression-free patients with HDA or high CRP was 40.4% and 40.0%, 43.1% and 38.2%, and 69.8% and 61.5%, respectively. Among MDA or low CRP patients, both golimumab doses showed similar prevention of joint destruction. Among HDA or high CRP patients, a shorter disease duration and higher TSS/disease duration ratio were associated with joint destruction.Both doses of golimumab (50 or 100 mg) prevented joint destruction in MDA or low CRP patients, but 100 mg was better for HDA or high CRP patients with a shorter disease duration or higher TSS/disease duration ratio.
- Subjects :
- Adult
Male
medicine.medical_specialty
Administration, Oral
Placebo
Severity of Illness Index
Gastroenterology
Arthritis, Rheumatoid
Young Adult
03 medical and health sciences
Basal (phylogenetics)
0302 clinical medicine
Rheumatology
Internal medicine
Post-hoc analysis
medicine
Humans
In patient
030212 general & internal medicine
Aged
030203 arthritis & rheumatology
Dose-Response Relationship, Drug
biology
business.industry
C-reactive protein
Antibodies, Monoclonal
Middle Aged
medicine.disease
Golimumab
Surgery
C-Reactive Protein
Methotrexate
Treatment Outcome
Antirheumatic Agents
Rheumatoid arthritis
Disease Progression
biology.protein
Drug Therapy, Combination
Female
business
Biomarkers
Follow-Up Studies
medicine.drug
Subjects
Details
- ISSN :
- 14397609 and 14397595
- Volume :
- 26
- Database :
- OpenAIRE
- Journal :
- Modern Rheumatology
- Accession number :
- edsair.doi.dedup.....e7bfb550bb0128f39ccc1b0003316889
- Full Text :
- https://doi.org/10.3109/14397595.2015.1086041